13
Nov
Off

Response after single treatment with canakinumab predicts which patients will benefit most

Via Top Health News -- ScienceDaily

A pre-specified analysis on CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) that identifies a simple, clinical method to define patient groups most likely to benefit from long-term canakinumab treatment.

View original post here:

%d bloggers like this: